Quantcast
Home > Quotes > BLPH

Bellerophon Therapeutics, Inc. Common Stock (BLPH) Quote & Summary Data

BLPH 
$0.71
*  
0.065
10.08%
Get BLPH Alerts
*Delayed - data as of Jul. 18, 2019  -  Find a broker to begin trading BLPH now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    BLPH After Hours
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
$ 0.61 / $ 0.75
Today's High / Low
$ 0.73 / $ 0.6568
Share Volume
418,891
50 Day Avg. Daily Volume
199,450
Previous Close
$ 0.645
52 Week High / Low
$ 2.80 / $ 0.47
Market Cap
48,923,803
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %

Intraday Chart

Shares Traded

Share Volume:
418,891
50 Day Avg. Daily Volume:
199,450

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -0.33

Trading Range

The current last sale of $0.71 is 51.06% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 0.73 $ 2.80
 Low: $ 0.6568 $ 0.47

Company Description (as filed with the SEC)

We are a clinical-stage therapeutics company focused on developing innovative products that address significant unmet medical needs in the treatment of cardiopulmonary diseases. Our focus is the continued development of our nitric oxide therapy for patients with pulmonary hypertension, or PH, using our proprietary pulsatile nitric oxide delivery platform, INOpulse. In 2016, we began developing INOpulse for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD), which includes PH associated with idiopathic pulmonary fibrosis (PH-IPF) as well as other pulmonary fibrosing diseases. During May 2017, we announced the completion of our Phase 2 clinical trial using INOpulse therapy to treat PH-IPF. The clinical data showed that INOpulse was associated with clinically meaningful improvements in hemodynamics and exercise capacity in difficult-to-treat PH-IPF patients.  ... More ...  



Risk Grade

Where does BLPH fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 0.66
Open Date:
Jul. 18, 2019
Close Price:
$ 0.71
Close Date:
Jul. 18, 2019


Consensus Recommendation

Analyst Info